Re: Intellia's CrispR gene therapy trial for HAE is not a risk to BCRX
Yes, people should recognize that gene editing is not a precise science yet. It may be possible to edit some cells in vitro, then find and expand those that are just what you want, and use those in the patient. But as an efficient treatment, this is years away. Todays drop is a mistake. I expect a big jump as we approach the August 4 Q2 report.